Ariad Pharmaceuticals Inc fka ARIA

[DonShimoda]

You asked

What percent of patients on Gleevec develop a mutation or resistance? 10%? Less than 10%?

Answer: More than 10%

Eventually, 30% of pts become resistant to gleevec(about half from mutations) and 50% become resistant to sprycel and/or tasigna.

It's a significant market whether AP534 eventually gets approved as first line treatment or not.